Literature DB >> 33021749

Japanese Clinical Practice Guideline for Diabetes 2019.

Eiichi Araki1, Atsushi Goto2, Tatsuya Kondo3, Mitsuhiko Noda4, Hiroshi Noto5, Hideki Origasa6, Haruhiko Osawa7, Akihiko Taguchi8, Yukio Tanizawa8, Kazuyuki Tobe9, Narihito Yoshioka10.   

Abstract

Entities:  

Keywords:  Diabetes; Diagnosis; Guideline; Treatment

Mesh：

Year:  2020        PMID： 33021749      PMCID： PMC7378414          DOI： 10.1111/jdi.13306

Source DB:  PubMed          Journal:  J Diabetes Investig        ISSN： 2040-1116            Impact factor:   4.232


× No keyword cloud information.
  406 in total

1.  Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.

Authors:  G Charpentier; F Fleury; M Kabir; L Vaur; S Halimi
Journal:  Diabet Med       Date:  2001-10       Impact factor: 4.359

2.  ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents.

Authors:  Oscar Rubio-Cabezas; Andrew T Hattersley; Pål R Njølstad; Wojciech Mlynarski; Sian Ellard; Neil White; Dung Vu Chi; Maria E Craig
Journal:  Pediatr Diabetes       Date:  2014-09       Impact factor: 4.866

3.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.

Authors:  L Niskanen; T Hedner; L Hansson; J Lanke; A Niklason
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

Review 4.  Evidence-based management of hyperglycemic emergencies in diabetes mellitus.

Authors:  Ebenezer A Nyenwe; Abbas E Kitabchi
Journal:  Diabetes Res Clin Pract       Date:  2011-10-05       Impact factor: 5.602

5.  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael Farber; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carol Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann
Journal:  Arch Intern Med       Date:  2005-04-25

Review 6.  Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.

Authors:  Mohsen Janghorbani; Rob M Van Dam; Walter C Willett; Frank B Hu
Journal:  Am J Epidemiol       Date:  2007-06-16       Impact factor: 4.897

7.  Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: A network meta-analysis.

Authors:  Zimeng Li; Yi Li; Yulong Liu; Wenbo Xu; Qing Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-10-25       Impact factor: 3.738

Review 8.  Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction.

Authors:  Fumiaki Imamura; Laura O'Connor; Zheng Ye; Jaakko Mursu; Yasuaki Hayashino; Shilpa N Bhupathiraju; Nita G Forouhi
Journal:  BMJ       Date:  2015-07-21

Review 9.  Dose-Response Relationship between Dietary Magnesium Intake and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Regression Analysis of Prospective Cohort Studies.

Authors:  Xin Fang; Hedong Han; Mei Li; Chun Liang; Zhongjie Fan; Jan Aaseth; Jia He; Scott Montgomery; Yang Cao
Journal:  Nutrients       Date:  2016-11-19       Impact factor: 5.717

Review 10.  Roux-en-Y Gastric Bypass Versus Medical Treatment for Type 2 Diabetes Mellitus in Obese Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yong Yan; Yanhua Sha; Guoxiang Yao; Shiguang Wang; Fanzhi Kong; Haijun Liu; Guangjun Zhang; Haiqing Zhang; Cheng Hu; Xueli Zhang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889
View more
  47 in total

1.  Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.

Authors:  Hiroshi Takahashi; Yuka Suganuma; Takayuki Ohno; Rimei Nishimura
Journal:  Diabetol Int       Date:  2022-03-16

Review 2.  Adult-onset autoimmune diabetes.

Authors:  Raffaella Buzzetti; Ernesto Maddaloni; Jason Gaglia; R David Leslie; F Susan Wong; Bernhard O Boehm
Journal:  Nat Rev Dis Primers       Date:  2022-09-22       Impact factor: 65.038

3.  Hypoglycemic coma in an elderly adult switched from twice-daily vildagliptin to once-daily glimepiride to improve drug adherence.

Authors:  Shunsuke Tominari; Megumi Yasuda; Takehiro Kato; Mayu Sakai; Sodai Kubota; Kenta Nonomura; Tokuyuki Hirose; Ken Takao; Yanyan Liu; Masami Mizuno; Takuo Hirota; Katsumi Iizuka; Tetsuya Suwa; Yukio Horikawa; Daisuke Yabe
Journal:  Diabetol Int       Date:  2021-05-05

4.  Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).

Authors:  Hiroshi Maegawa; Kazuyuki Tobe; Ichiro Nakamura; Satoshi Uno
Journal:  Diabetol Int       Date:  2021-03-24

5.  A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

Authors:  Yutaka Seino; Kohei Kaku; Takashi Kadowaki; Taro Okamoto; Asako Sato; Masayoshi Shirakawa; Edward A O'Neill; Samuel S Engel; Keith D Kaufman
Journal:  Diabetes Obes Metab       Date:  2021-02-28       Impact factor: 6.577

6.  Lifestyle changes and their impact on glycemic control and weight control in patients with diabetes during the coronavirus disease 2019 pandemic in Japan.

Authors:  Mitsuyoshi Takahara; Hirotaka Watanabe; Toshihiko Shiraiwa; Yoshifumi Maeno; Kaoru Yamamoto; Yuka Shiraiwa; Yoko Yoshida; Norio Nishioka; Naoto Katakami; Iichiro Shimomura
Journal:  J Diabetes Investig       Date:  2021-05-07       Impact factor: 4.232

7.  A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.

Authors:  Takashi Kadowaki; Yutaka Seino; Kohei Kaku; Taro Okamoto; Miho Kameya; Asako Sato; Tomona Hirano; Nobuyuki Oshima; Ira Gantz; Edward A O'Neill; Samuel S Engel
Journal:  Diabetes Obes Metab       Date:  2021-02-17       Impact factor: 6.577

8.  A combined index of waist circumference and muscle quality is associated with cardiovascular disease risk factor accumulation in Japanese obese patients: a cross-sectional study.

Authors:  Kentaro Ikeue; Toru Kusakabe; Kazuya Muranaka; Hajime Yamakage; Takayuki Inoue; Kojiro Ishii; Noriko Satoh-Asahara
Journal:  Endocrine       Date:  2022-04-19       Impact factor: 3.925

9.  Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia.

Authors:  Hayato Tada; Nobuko Kojima; Kan Yamagami; Akihiro Nomura; Atsushi Nohara; Soichiro Usui; Kenji Sakata; Noboru Fujino; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

Review 10.  Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.

Authors:  Wajd Alkabbani; John-Michael Gamble
Journal:  Drug Des Devel Ther       Date:  2021-07-14       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.